The main research interest regards sodium channels and their blockers
- Curriculum Vitae
- Office hour
Dr. Mirko Rivara took his degree in Pharmaceutical Chemistry and Technology at the University of Parma in 2000 (110/110 cum laude) and he received the Ph.D. in Pharmaceutical Chemistry and Technology in 2004 (Title: Design and synthesis of H3-antagonists with improved access to the central nervous sistem).
During the Ph.D. period he joined for five months, March-July 2002, the Department of Organic Chemistry at the University of Milan (I).
From February 1, 2004, he is Researcher (Assistant Professor) at the Faculty of Pharmacy of the University of Parma (I).
During the following periods August 2011-January 2012, January 2013-May 2013 and February 2015-April 2015 he joyned the Department of Anesthesiology at the University of Virginia as visiting professor.
Dr. Mirko Rivara scientific activity is characterized by the design and synthesis of compounds with activity towards various CNS disorders with a great attention to sodium channel blockers and antiepileptic drugs.
His interest is focused on new synthetic tecniques and methodologies useful to obtain small and medium sized libraries of small organic molecules.
During these years Dr Mirko Rivara gained useful skills regarding classic and innovative metodologies in organic chemistry such as: solid phase synthesis, parallel synthesis, combinatorial chemistry and microwave assisted organic chemistry, moreover he acquired experience in structural analysis of organic compounds using NMR spettroscopy.
Recently he had the opportunity to acquire expertise in electrophysiology working, at the University of Virginia, on in vitro and ex vivo models of epilepsy.
Any other day previous appointment
Anno accademico di erogazione: 2020/2021
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2019/2020
Anno accademico di erogazione: 2019/2020
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2018/2019
Anno accademico di erogazione: 2018/2019
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2017/2018
Lines of research
NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet syndromeYear: 2020Author/s: Weuring W. J., Singh S., Volkers L., Rook M. B., Van't Slot R. H., Bosma M., Inserra M., Vetter I., Verhoeven-Duif N. M., Braun K. P. J., Rivara M., Koeleman B. P. C.
3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell lineYear: 2020Author/s: Alessio Malacrida, Mirko Rivara, Alessandro Di Domizio, Giacomo Cislaghi, Mariarosaria Miloso, Valentina Zuliani, Gabriella Nicolini
Year: 2019Author/s: PATEL Manoj K, RIVARA Mirko
Year: 2018Author/s: Botta, Lorenzo, Rivara, Mirko, Zuliani, Valentina, Radi, Marco
Year: 2018Author/s: PATEL Manoj, RIVARA M
Parco Area delle Scienze 27/A